218 related articles for article (PubMed ID: 26919249)
21. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
[TBL] [Abstract][Full Text] [Related]
22. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance].
Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP
Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of Low density lipoprotein Receptor-related Protein 1 (LRP-1) and matrix metalloproteinase-9 (MMP-9) in prostate gland: From normal to malignant lesions.
Gilardoni MB; Remedi MM; Oviedo M; Dellavedova T; Sarría JP; Racca L; Dominguez M; Pellizas CG; Donadio AC
Pathol Res Pract; 2017 Jan; 213(1):66-71. PubMed ID: 27931798
[TBL] [Abstract][Full Text] [Related]
24. Promotion of epithelial hyperplasia by interleukin-8-CXCR axis in human prostate.
Smith DK; Hasanali SL; Wang J; Kallifatidis G; Morera DS; Jordan AR; Terris MK; Klaassen Z; Bollag R; Lokeshwar VB; Lokeshwar BL
Prostate; 2020 Sep; 80(12):938-949. PubMed ID: 32542667
[TBL] [Abstract][Full Text] [Related]
25. Profile of NF-κBp(65/NFκBp50) among prostate specific antigen sera levels in prostatic pathologies.
Bouraoui Y; Ben Jemaa A; Rodriguez G; Ben Rais N; Fraile B; Paniagua R; Sellemi S; Royuela M; Oueslati R
Pathol Biol (Paris); 2012 Oct; 60(5):301-5. PubMed ID: 21889270
[TBL] [Abstract][Full Text] [Related]
26. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia.
Cohen P; Peehl DM; Baker B; Liu F; Hintz RL; Rosenfeld RG
J Clin Endocrinol Metab; 1994 Nov; 79(5):1410-5. PubMed ID: 7525636
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia.
Jackson MW; Bentel JM; Tilley WD
J Urol; 1997 Jun; 157(6):2323-8. PubMed ID: 9146664
[TBL] [Abstract][Full Text] [Related]
28. [Expressions of the androgen receptor in normal prostate, benign prostatic hyperplasia and prostate cancer].
Zeng R; Liu ZY; Sun YH; Xu CL; Gao X; Jiao L
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):967-72. PubMed ID: 21218636
[TBL] [Abstract][Full Text] [Related]
29. The anti-hyperplasia, anti-oxidative and anti-inflammatory properties of Qing Ye Dan and swertiamarin in testosterone-induced benign prostatic hyperplasia in rats.
Wu X; Gu Y; Li L
Toxicol Lett; 2017 Jan; 265():9-16. PubMed ID: 27866977
[TBL] [Abstract][Full Text] [Related]
30. [Expression of HIF-1α in the prostatic tissue of mice with high-fat diet-induced obesity].
Li K; Yang Q; Gui SK; Liu ZW; Wang R; Liu XY
Zhonghua Nan Ke Xue; 2019 Jun; 25(6):483-488. PubMed ID: 32223080
[TBL] [Abstract][Full Text] [Related]
31. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V
J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606
[TBL] [Abstract][Full Text] [Related]
32. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
33. [Expressions of SIgA and alpha 1-AR in benign prostatic hyperplasia combined with chronic prostatitis and their implications].
Gao WJ; Wang YM; Wang CH; Yang XK; Wan L; Li WP
Zhonghua Nan Ke Xue; 2013 Apr; 19(4):315-20. PubMed ID: 23678709
[TBL] [Abstract][Full Text] [Related]
34. Association of elevated interleukin-17 and angiopoietin-2 with prostate size in benign prostatic hyperplasia.
Arivazhagan J; Nandeesha H; Dorairajan LN; Sreenivasulu K
Aging Male; 2017 Jun; 20(2):115-118. PubMed ID: 28590830
[TBL] [Abstract][Full Text] [Related]
35. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
36. [Identification of low-molecular weight prostate-specific antigen(PSA) and lactoferrin in the prostatic secretion of benign prostatic hyperplasia].
Xu KX; Wang XF
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Dec; 38(6):648-52. PubMed ID: 17173089
[TBL] [Abstract][Full Text] [Related]
37. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
Shariat SF; Ashfaq R; Roehrborn CG; Slawin KM; Lotan Y
J Urol; 2005 Nov; 174(5):2046-50. PubMed ID: 16217391
[TBL] [Abstract][Full Text] [Related]
38. Organ-wide telomeric status in diseased and disease-free prostatic tissues.
Heaphy CM; Fleet TM; Treat EG; Lee SJ; Smith AY; Davis MS; Griffith JK; Fischer EG; Bisoffi M
Prostate; 2010 Sep; 70(13):1471-9. PubMed ID: 20687220
[TBL] [Abstract][Full Text] [Related]
39. Correlation between molecular biomarkers and risk factors for the clinical progression of benign prostatic hyperplasia using tissue microarray immunostaining.
Ma D; Yang B; Zhou Z; Pan D; Zhang X
Chin Med J (Engl); 2014; 127(23):4031-5. PubMed ID: 25430444
[TBL] [Abstract][Full Text] [Related]
40. Cellular senescence in the pathogenesis of benign prostatic hyperplasia.
Castro P; Giri D; Lamb D; Ittmann M
Prostate; 2003 Apr; 55(1):30-8. PubMed ID: 12640658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
